Wall Street brokerages forecast that Zoetis Inc (NYSE:ZTS) will announce earnings of $0.66 per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Zoetis’ earnings. The lowest EPS estimate is $0.65 and the highest is $0.69. Zoetis reported earnings per share of $0.47 in the same quarter last year, which would suggest a positive year over year growth rate of 40.4%. The business is expected to issue its next earnings report on Thursday, February 15th.

On average, analysts expect that Zoetis will report full-year earnings of $2.37 per share for the current fiscal year, with EPS estimates ranging from $2.34 to $2.40. For the next year, analysts expect that the company will post earnings of $2.72 per share, with EPS estimates ranging from $2.69 to $2.79. Zacks’ EPS averages are a mean average based on a survey of analysts that cover Zoetis.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.02. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The firm’s revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.52 EPS.

A number of brokerages recently issued reports on ZTS. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a research note on Thursday, October 12th. Cantor Fitzgerald reiterated a “buy” rating and set a $75.00 price objective on shares of Zoetis in a research note on Wednesday, September 6th. BidaskClub downgraded Zoetis from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. Morgan Stanley upped their price target on Zoetis from $61.00 to $70.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. Finally, Piper Jaffray Companies set a $73.00 price target on Zoetis and gave the stock a “buy” rating in a research note on Friday, August 25th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $68.53.

Shares of Zoetis (NYSE:ZTS) traded up $0.46 during trading hours on Tuesday, hitting $72.23. The company had a trading volume of 1,939,851 shares, compared to its average volume of 2,757,257. The company has a market cap of $35,026.28, a P/E ratio of 32.97, a PEG ratio of 2.15 and a beta of 1.06. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. Zoetis has a 52 week low of $50.57 and a 52 week high of $72.79.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be paid a $0.126 dividend. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. The ex-dividend date is Thursday, January 18th. This represents a $0.50 dividend on an annualized basis and a yield of 0.70%. Zoetis’s dividend payout ratio (DPR) is presently 22.11%.

A number of hedge funds have recently added to or reduced their stakes in ZTS. Janus Henderson Group PLC increased its stake in shares of Zoetis by 7,717.4% during the second quarter. Janus Henderson Group PLC now owns 5,809,086 shares of the company’s stock valued at $362,372,000 after buying an additional 5,734,776 shares during the period. Alliancebernstein L.P. increased its stake in shares of Zoetis by 55.4% during the second quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock valued at $646,905,000 after buying an additional 3,695,449 shares during the period. BlackRock Inc. increased its stake in shares of Zoetis by 3.9% during the second quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock valued at $2,338,957,000 after buying an additional 1,412,829 shares during the period. AJO LP increased its stake in shares of Zoetis by 4,506.8% during the second quarter. AJO LP now owns 1,271,425 shares of the company’s stock valued at $79,311,000 after buying an additional 1,243,826 shares during the period. Finally, Thrivent Financial For Lutherans increased its stake in shares of Zoetis by 642.7% during the second quarter. Thrivent Financial For Lutherans now owns 1,336,033 shares of the company’s stock valued at $83,342,000 after buying an additional 1,156,142 shares during the period. Institutional investors and hedge funds own 93.33% of the company’s stock.

WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/12/zacks-analysts-expect-zoetis-inc-zts-will-announce-earnings-of-0-66-per-share.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Get a free copy of the Zacks research report on Zoetis (ZTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.